To amend the Federal Food, Drug, and Cosmetic Act with respect to precision medicine.

Bill: 114-hr-2455
Sponsor: full_name: Rep. Pitts, Joseph R. [R-PA-16]
Introduced: 2015-05-19
Policy area: Health
Subjects: Administrative law and regulatory procedures

Department of Health and Human Services

Drug safety, medical device, and laboratory regulation

Prescription drugs
Latest action: action_date: 2015-05-22
text: Referred to the Subcommittee on Health.

Summaries:
action_date: 2015-05-19
action_desc: Introduced in House
text: <p>This bill amends the Federal Food, Drug, and Cosmetic Act to require the Food and Drug Administration (FDA) to define &quot;precision drug or biological product.&quot; (Precision medications are commonly understood to be treatments for those patients who are likely to respond to the medication based on a biomarker, which is a biological characteristic such as a genetic factor.)</p> <p>The FDA must issue and periodically update guidance that addresses the development and use of biomarkers to identify the subset of patients that are likely to respond to a medication. </p> The FDA may rely upon data previously submitted for a different approved medication or indication to expedite the clinical development of a precision medication that has been designated for the treatment of a serious or rare condition.

tv_txt: I 114th CONGRESS 1st Session H. R. 2455 IN THE HOUSE OF REPRESENTATIVES May 19, 2015 Mr. Pitts introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Federal Food, Drug, and Cosmetic Act with respect to precision medicine.

1. Precision medicine guidance and other programs of Food and Drug Administration Chapter V of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 351 et seq. ) is amended by adding at the end the following: J Precision Medicine 591. General agency guidance on precision medicine (a) In general The Secretary shall issue and periodically update guidance to assist sponsors in the development of a precision drug or biological product. Such guidance shall— (1) define the term precision drug or biological product ; and (2) address the topics described in subsection (b). (b) Certain issues The topics to be addressed by guidance under subsection (a) are— (1) the evidence needed to support the use of biomarkers (as defined in section 507(e)) that identify subsets of patients as likely responders to therapies in order to streamline the conduct of clinical trials; (2) recommendations for the design of studies to demonstrate the validity of a biomarker as a predictor of drug or biological product response; (3) the manner and extent to which a benefit-risk assessment may be affected when clinical trials are limited to patient population subsets that are identified using biomarkers; (4) the development of companion diagnostics in the context of a drug development program; and (5) considerations for developing biomarkers that aid prescribing decisions for a drug or biological product, and when information regarding a biomarker may be included in the labeling for a drug or biological product approved under section 505 of this Act or section 351 of the Public Health Service Act. (c) Date certain for initial guidance The Secretary shall issue guidance under subsection (a) not later than 18 months after the date of the enactment of the 21st Century Cures Act. 592. Precision medicine regarding orphan-drug and expedited-approval programs In the case of an application for a precision drug or biological product under section 505(b)(1), or section 351(a) of the Public Health Service Act, that has been designated under section 526 as a drug for a rare disease for a serious condition, the Secretary may— (1) consistent with applicable standards for approval, rely upon data or information previously developed by the sponsor of the precision drug or biological product for a prior approved drug or indication (or that of another sponsor, provided the sponsor of the precision drug or biological product has obtained a contractual right of reference to such other sponsor’s data and information) in order to expedite clinical development for a precision drug or indication that is using the same or similar approach as that of the prior approved drug or indication; and (2) as appropriate under section 506, consider the application for approval of such precision drug or biological product to be eligible for expedited review, including under section 506(c) (relating to accelerated approval). .